Brief: Ocumension Therapeutics Says Unit Enters Promotion Agreement With Viatris Pharmaceuticals
01/06/2022 15:40
June 1 (Reuters) - Ocumension Therapeutics 1477.HK :
* UNIT ENTERED INTO PROMOTION AGREEMENT WITH VIATRIS
PHARMACEUTICALS CO., LTD
* UNDER AGREEMENT, UNIT SHALL PAY VIATRIS CHINA RMB30
MILLION FOR
EXCLUSIVE LICENSE TO PROMOTE AZELASTINE HYDROCHLORIDE EYE DROPS
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application